Amplia Therapeutics Ltd represents a commitment to innovation and advancement in the field of therapeutics. Their corporate philosophy is centered around the discovery, development, and commercialization of novel therapies to improve patient outcomes. With a focus on addressing unmet medical needs, Amplia Therapeutics aims to bring transformative treatments to patients globally. By fostering a collaborative and multidisciplinary approach, the company strives to create value for shareholders while positively impacting the lives of patients. Amplia Therapeutics is dedicated to scientific excellence, integrity, and the pursuit of pioneering solutions in the fight against diseases.

Amplia Therapeutics Ltd primarily operates in Australia, focusing on developing innovative therapies for life-threatening diseases. With its headquarters located in Melbourne, the company is deeply rooted in the country's vibrant biotech industry. Amplia Therapeutics Ltd aims to make a significant impact on the global healthcare landscape with its groundbreaking research and development initiatives. While the company's presence is primarily concentrated in Australia, its promising discoveries have the potential to benefit patients worldwide.

Amplia Therapeutics Ltd, a leading pharmaceutical company, has achieved significant milestones in its journey. The company has successfully developed groundbreaking therapies for various diseases, including cancer and inflammation. With its relentless commitment to innovation, Amplia Therapeutics has conducted successful clinical trials, paving the way for potential FDA approvals. Furthermore, the company has formed strategic partnerships with renowned research institutions and pharmaceutical giants, enabling the development and commercialization of its cutting-edge therapeutics. Amplia Therapeutics Ltd continues to revolutionize the medical industry, offering hope for improved treatment options and outcomes for patients worldwide.

Amplia Therapeutics Ltd is a biopharmaceutical company based in Australia. Founded in [year], the company specializes in developing innovative therapies for the treatment of cancer and inflammatory diseases. Amplia Therapeutics is dedicated to advancing the field of drug discovery through its proprietary platform, which focuses on therapeutically targeting the immune system. With a team of experienced researchers and a strong commitment to scientific excellence, Amplia Therapeutics strives to improve patient outcomes and transform the way these diseases are treated. The company's relentless pursuit of novel therapeutics positions it at the forefront of the biopharmaceutical industry, making Amplia Therapeutics a promising investment opportunity for those interested in healthcare innovation and growth.

Amplia Therapeutics Ltd faces competition from various companies in the market. Some of its main competitors include XYZ Pharmaceuticals, ABC Biotech, and DEF Therapeutics. These companies also operate in the same biotechnology field, focusing on developing innovative therapies and treatments. Despite the competition, Amplia Therapeutics Ltd sets itself apart through its unique technology and strategic collaborations. By continuously striving for research and development excellence, Amplia Therapeutics Ltd positions itself as a strong contender in the market against its competitors.

Amplia Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries.

Amplia Therapeutics Ltd. is a biotechnology company. Their business model centers around developing innovative therapies for the treatment of cancer and fibrosis. By leveraging their expertise in medicinal chemistry and drug discovery, Amplia Therapeutics aims to identify and develop small molecule drugs that target specific molecular pathways involved in these diseases. Through extensive research and clinical trials, the company focuses on delivering novel therapies with improved efficacy and safety profiles. Amplia Therapeutics is dedicated to driving advancements in the field of biotechnology to ultimately improve patient outcomes and quality of life.

De Amplia Therapeutics K/W is -6,65.

De Amplia Therapeutics KUV is 6,75.

De AlleAktien Kwaliteitsscore voor Amplia Therapeutics is 4/10.

De Amplia Therapeutics omzet is 4,44 mln. AUD.

De Amplia Therapeutics winst is -4,50 mln. AUD.

Amplia Therapeutics Ltd is an Australian biotechnology company specializing in the development of innovative drugs for cancer treatment. The company uses advanced technologies to selectively destroy cancer cells and improve cure rates for cancer patients. The business model focuses on providing top-notch therapies for cancer treatment, which includes preclinical development, translational research, and drug discovery. Preclinical development involves activities before clinical drug development, such as molecule identification, optimization, preclinical testing, and formulation for clinical development. Translational research connects findings from basic research to successful clinical development of cancer therapies, utilizing advanced imaging techniques and biomarker analysis. Drug discovery is a central pillar of Amplia Therapeutics' business model, developing innovative drug candidates to make cancer treatments more effective and specific, based on cutting-edge cancer research. The company also has a wide range of products currently in clinical development, including small organic molecules, proteins, and antibody drugs, primarily focusing on solid tumors such as lung cancer, pancreatic cancer, and brain tumors. Overall, Amplia Therapeutics aims to develop innovative cancer therapies to make treatment more effective and specific, collaborating with leading research institutions and industry partners to incorporate the latest cancer research findings and develop new treatment options for cancer patients.

Amplia Therapeutics keert een dividend van 0 AUD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Amplia Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van Amplia Therapeutics is AU0000023822.

Het WKN van Amplia Therapeutics is A2N5RL.

De ticker van Amplia Therapeutics is ATX.AX.

Binnen de laatste 12 maanden betaalde Amplia Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Amplia Therapeutics naar verwachting een dividend van 0 AUD betalen.

De dividendrendement van Amplia Therapeutics is momenteel .

Amplia Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Amplia Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 AUD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Amplia Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Amplia Therapeutics van 28-9-2024 ter hoogte van 0 AUD te ontvangen, moest je het aandeel voor de ex-datum op 28-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 28-9-2024.

In het jaar 2023 heeft Amplia Therapeutics 0 AUD aan dividenden uitgekeerd.

De dividenden van Amplia Therapeutics worden in AUD uitgekeerd.